Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3)
What is the purpose of this trial?
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
- Ages55 - 90 years
- Trial withAlzheimer's Therapeutic Research Institute
- Start Date03/27/2017
- End Date10/30/2021
- Last Updated02/22/2018
- Study HIC#1608018296